Please login to the form below

Not currently logged in
Email:
Password:

epigenetics

This page shows the latest epigenetics news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca to explore link between epigenetics and respiratory diseases

AstraZeneca to explore link between epigenetics and respiratory diseases

AstraZeneca to explore link between epigenetics and respiratory diseases. Joins forces with Asthma UK, the British Lung Foundation and MRC Technology. ... Epigenetics are changes in the expression of genes attributed to lifestyle factors affecting the

Latest news

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2016 Deal Watch November 2016

    licence, collaboration. 207.5. Proterosos biostructures/ Merck &Co (MSD). second collaboration to develop small molecules against an additional epigenetic target for various cancers.

  • Opening up innovation Opening up innovation

    So that is really about the late-stage portfolio. We [are still] focused on three areas in oncology.” These are cancer epigenetics, immuno-oncology and cell and gene therapy in oncology. “

  • Deal Watch January 2016 Deal Watch January 2016

    Tensha has developed an epigenetic technology that disrupts bromodomain and extra terminal domain (BET) proteins in order to develop potential treatments for cancer. ... 535. Rodin/ Biogen. Collaboration. Multi-year neuronal epigenetics research

  • Deal Watch October 2015 Deal Watch October 2015

    Proteros' epigenetics technology and structure guided discovery platform for oncology targets (discovery).

  • Pharma deals in August 2015 Pharma deals in August 2015

    This situation occurred when Genentech/Roche elected not to go further with their option to acquire the epigenetics drug discovery company, Constellation Pharmaceuticals.

More from intelligence
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Professor Thomas Cech joins Storm Therapeutics Professor Thomas Cech joins Storm Therapeutics

    mature into a world leading therapeutics company targeting RNA epigenetic modulation.”.

  • Storm Therapeutics bolsters its team Storm Therapeutics bolsters its team

    As a clinician-scientist at the University of Melbourne, Professor Dawson has experience in epigenetics having spent several years researching epigenetic regulation of leukaemia stem cells. ... Keith Blundy, chief executive officer of Storm Therapeutics,

  • Storm Therapeutics strengthens its board Storm Therapeutics strengthens its board

    RNA epigenetic modulation is an exciting area of science with real potential to deliver new targeted cancer therapies. ... We look forward to Paul’s input on development and positioning of Storm’s emerging RNA epigenetics platform and programmes.”.

  • Rubius Therapeutics strengthens senior team Rubius Therapeutics strengthens senior team

    He most recently served as the senior vice president and head of the cancer epigenetics department at GlaxoSmithKline, where he was responsible for overall strategy, as well as identification and validation ... of new epigenetic targets and advancing

  • Paul Stockdale joins Oxford BioDynamics as CFO Paul Stockdale joins Oxford BioDynamics as CFO

    A spin-out from Oxford University, Oxford BioDynamics focuses on the discovery and development of epigenetic biomarkers based on regulatory genome architecture.

More from appointments
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics